iBio, Inc. (IBIO) SEC Filings

iBio, Inc. (IBIO) is asking stockholders at the October 14, 2026 annual meeting to elect two Class III directors (William D. Clark and Gary Sender), ratify Grassi & Co., CPAs, P.C. as auditor for the year ending June 30, 2027, and approve an advisory Say‑on‑Pay resolution for named executive officer compensation.

The board also seeks approval to amend the certificate of incorporation to increase authorized common stock from 275,000,000 to 500,000,000 shares, which would raise authorized but unissued common stock from 81,414,117 to 306,414,117 shares as of the record date. Another key proposal would amend the 2023 Omnibus Incentive Plan’s evergreen formula so that annual increases through 2029 are based on both outstanding common stock and Pre‑Funded Warrants, of which 93,382,863 are outstanding. The company notes these changes could affect dilution and may have anti‑takeover effects. A separate proposal would allow adjournment of the meeting to solicit more votes if needed for the share increase or plan amendment.

iBio, Inc. (IBIO) is a clinical-stage biotechnology company focused on AI-guided precision antibodies for obesity and related cardiometabolic and cardiopulmonary diseases. The company’s AI Drug Discovery Platform combines epitope steering, generative AI (StableHu), and mammalian display to rapidly generate development-ready biologics.

Lead program IBIO-600, an anti-myostatin antibody licensed from AstralBio, entered a Phase 1 single-ascending-dose trial in overweight or obese adults in June 2026; 31 participants across four cohorts will be followed for about nine months, with advancement to multiple-ascending-dose planned. IBIO-610, an Activin E inhibitor targeting fat-selective weight loss and GLP-1 combination use, is expected to start first-in-human studies in the first half of 2027. IBIO-800, a myostatin × Activin A bispecific for obesity and PH-HFpEF, is in late discovery with a development candidate nominated in June 2026.

iBio has multiple exclusive licenses with AstralBio (myostatin, Activin E, and amylin programs) featuring $750,000 upfronts and up to $28 million in milestones per program, plus low- to mid-single-digit sublicense fees. The 2022 RubrYc asset purchase added an AI discovery platform and oncology assets, which are now positioned for partnering. The company reported $57.5 million in non-affiliate equity market value and 64.3 million shares outstanding, and increased R&D investment to support its expanding pipeline and AI infrastructure.

iBio, Inc. (IBIO), a clinical-stage biotechnology company focused on long-acting antibody therapeutics, reported results for the fiscal year ended June 30, 2026 and highlighted its transition into the clinic with initiation of a Phase 1 trial for IBIO-600, an anti-myostatin antibody targeting muscle preservation and body composition.

Revenue was $0.1 million, down from $0.4 million in 2025. Research and development expenses rose to $19.6 million from $8.3 million, driven by higher spending on consultants, non-human primate studies, CMC activities, and a $2.5 million development milestone. An impairment charge of $5.0 million was recorded on the IBIO-101 intangible asset. Net loss widened to $33.0 million from $18.4 million. iBio reported cash, cash equivalents and investments in debt securities of approximately $88.0 million as of June 30, 2026, with total stockholders’ equity of $85.7 million, and stated that successful financings extended its cash runway into fiscal year 2028 while it advances its obesity and cardiometabolic pipeline.

iBio, Inc. (IBIO) is asking stockholders at its October 14, 2026 annual meeting to elect two Class III directors (William D. Clark and Gary Sender), ratify Grassi & Co. as auditor for the June 30, 2027 fiscal year, and approve an advisory Say‑on‑Pay vote on executive compensation.

The Board seeks approval to amend the Certificate of Incorporation to increase authorized common shares from 275,000,000 to 500,000,000, which would raise authorized but unissued shares from about 81.4 million to about 306.4 million. It also proposes amending the 2023 Omnibus Incentive Plan’s “evergreen” so that the annual share increase through 2029 is tied to both outstanding common stock and a percentage of shares issuable upon exercise of pre‑funded warrants, then reverts to a 5% of outstanding common stock formula from 2030–2033.

The plan change is justified as aligning equity capacity with the large volume of pre‑funded warrants issued in recent financings, while the Board acknowledges the higher authorization could dilute voting power and potentially deter takeovers. A separate proposal would allow adjournment of the meeting to solicit additional votes for the share‑increase and plan‑amendment items.

Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of iBio, Inc. common stock through Series F warrants held by Lynx1 Master Fund LP. They report beneficial ownership of 2,807,016 shares of common stock issuable upon exercise of these warrants, which are subject to a 9.99% Blocker limiting exercisability. Based on 49,678,561 shares of common stock outstanding as of May 12, 2026, and assuming exercise of the warrants, this represents 5.4% of the class. The filers note that a prior Schedule 13G filed on February 17, 2026 inadvertently excluded these warrants from their reported beneficial ownership.

iBio, Inc. received an updated ownership report from Vestal Point Capital, LP and Ryan Wilder. They report beneficial ownership of 4,025,000 shares of common stock, including 1,425,000 shares issuable upon exercise of warrants.

The holding represents 7.9% of iBio’s common stock, based on 49,678,561 shares outstanding as of May 12, 2026 and assuming exercise of the reported warrants. All 4,025,000 shares are reported with shared voting and dispositive power and no sole voting or dispositive power. The shares and warrants are held by a Vestal Point fund and managed account, for which Vestal Point Capital acts as investment manager, and the filing states it should not be construed as an admission of beneficial ownership for any reporting person beyond what is reported.

Cormorant Asset Management, LP and Bihua Chen report a significant position in iBio, Inc. They report beneficial ownership of 5,117,481 shares of iBio common stock, representing 9.99% of the outstanding shares.

The position consists of 3,570,000 shares of common stock and warrants to purchase up to 11,586,340 additional shares, subject to a 9.99% beneficial ownership limitation that prevents further warrant exercises if it would push ownership above that level. All reported voting and dispositive power is shared, with no sole voting or dispositive power reported. The ownership percentage is based on 49,678,561 shares of iBio common stock outstanding as of May 12, 2026, as disclosed in iBio’s Form 10-Q for the quarter ended March 31, 2026.

Affinity Asset Advisors, LLC and Michael Cho report beneficial ownership of iBio, Inc. common stock. As of June 30, 2026, they beneficially own 5,068,882 shares of common stock, including 1,061,001 shares issuable upon exercise of warrants, subject to a 9.99% Beneficial Ownership Limitation.

The reported position represents approximately 9.99% of iBio’s outstanding common stock, based on 50,739,562 shares outstanding, which includes 49,678,561 shares outstanding as of May 12, 2026 and 1,061,001 warrant shares after applying the Beneficial Ownership Limitation. The securities are held through Affinity Healthcare Fund, LP, over which Affinity Asset Advisors, LLC, as investment manager, and Michael Cho, as managing member, may be deemed to share voting and dispositive power.

iBio, Inc. reported that its Chief Medical Officer, Molly Carr, received a grant of stock options covering 430,000 shares of common stock. The options have an exercise price of $1.40 per share and expire on July 30, 2036, with all 430,000 options held directly after the grant.

The award was granted on July 31, 2026 as an inducement award outside the iBio, Inc. 2023 Omnibus Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest 25% on the one-year anniversary of the grant date, with an additional 6.25% vesting every three months thereafter, contingent on Ms. Carr’s continued employment.